Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c- raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2227-2236

  Stevenson, James P ^a   Yao, Kang Shen ^a   Gallagher, Maryann ^a   Friedland, David ^a   Mitchell, Edith P ^a   Cassella, Amy ^a   Monia, Brett ^a   Jesse Kwoh, T ^a   Yu, Rosie ^a   Holmlund, Jon ^a   Andrew Dorr, F ^a   O'Dwyer, Peter J ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 69846A; RAF PROTEIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEVER; GENE EXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0032984099     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2227     Document Type: Article

References (34)

1. Daum G, Eisenmann-Tappe I, Fries HW, et al: The ins and outs of Raf kinases. Trends Biol Sci 19:474-480, 1994
2. Stokoe D, Macdonald S, Cadwallader K, et al: Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467, 1994
3. Nishida E, Gotoh Y: The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biol Sci 18:128-131, 1993
4. Shirasawa S, Furuse M, Yokoyama N, et al: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85-88, 1993
5. Stanton VP Jr, Cooper GM: Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 7:1171-1179, 1987
6. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
7. Storm SM, Rapp UR: Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201-210, 1993
8. Wang H-G, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-638, 1996
9. Kolch W, Heidecker G, Kochs G, et al: Protein kinase Cα activates Raf-1 by direct phosphorylation. Nature 364:249-252, 1993
10. Cornwell MM, Smith DE: A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268:15347-15350, 1993
11. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335, 1994
12. Monia BP, Johnston JF, Geiger T, et al: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 2:668-675, 1996
13. ISIS 5132 investigator's brochure. Carlsbad, CA, ISIS Pharmaceuticals Inc, 1998
14. Henry SP, Monteith D, Bennett F, et al: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409-420, 1997
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Leeds JM, Graham MJ, Truong L, et al: Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43, 1996
17. Horikoshi T, Danenberg KD, Stadibauer THW, et al: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116, 1992
18. O'Dwyer PJ, Szarka CE, Yao KS, et al: Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 98:1210-1217, 1996
19. Levine AS, Sivulich M, Wiernik PH, et al: Initial clinical trials in cancer patients of polyribosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res 39:1645-1650, 1979
20. Bishop MR, Iversen PL, Bayever E, et al: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320-1326, 1996
21. Barton C, Lemoine N: Antisense oligonucleotides targeting p53. J Clin Oncol 15:408, 1997 (letter)
22. Gewirtz AM, Luger S, Sokol D, et al: Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results. Blood 88:270a, 1996 (abstr 1069)
23. Webb A, Cunningham D, Cotter F, et al: BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet 349:1137-1141, 1997
24. Sikic BI, Yuen AR, Halsey J, et al: A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521) delivered by 21-day continuous infusion. Proc Am Soc Clin Oncol 16:212a, 1997 (abstr 741)
25. Nemunaitis J, Eckhardt G, Dorr A, et al: Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-alpha (PKC-alpha), in patients with refractory cancer. Proc Am Soc Clin Oncol 16:246a, 1997 (abstr 870)
26. Pisetsky DS: Immunologic consequences of nucleic acid therapy. Antisense Res Dev 5:219-225, 1995
27. Krieg AM, Yi AK, Matson S, et al: CpG motifs in bacterial DNA trigger direct B cell activation. Nature 374:546-549, 1995
28. Takamoto T, Yamamoto S, Kataoka T, et al: Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 4:119-122, 1994
29. Glover JM, Leeds JM, Mant TG, et al: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282: 1173-1180, 1997
30. Boggs RT, McGraw K, Condon T, et al: Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev 7:461-471, 1997
31. Barton CM, Lemoine NR: Antisense nucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 71:429-437, 1995
32. Smetsers TFCM, Linders EHP, van de Locht LTF, et al: An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol 96:377-381, 1997
33. Monia BP, Sasmor H, Johnston JF, et al: Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A 93:15481-15484, 1996
34. Holmlund J, Nemunaitis J, Schiller J, et al: Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol 17:210a, 1998 (abstr 811)